{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T02:22:50Z","timestamp":1768011770618,"version":"3.49.0"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210072, JP20fk0210064, JP20fk0210056, JP20fk0310101, JP20fk0210047, JP20fk0210048, JP20fk0210058, JP20fk0210066, and JP20fk0210067"],"award-info":[{"award-number":["JP20fk0210072, JP20fk0210064, JP20fk0210056, JP20fk0310101, JP20fk0210047, JP20fk0210048, JP20fk0210058, JP20fk0210066, and JP20fk0210067"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>A deteriorated liver functional reserve during systemic therapy for unresectable hepatocellular carcinoma (HCC) causes poor patient outcomes. We aimed to identify predictive factors associated with the deterioration of Child-Pugh score at 8 weeks after lenvatinib initiation. Patients with adequate clinical data and baseline preserved serum samples available were included. Baseline fibroblast growth factor (FGF)19 and 21, angiopoietin (ANG)2, and vascular endothelial growth factor (VEGF) levels were evaluated. Thirty-seven patients were included, and 6, 15, 14, and 2 experienced complete response, partial response, stable disease, and progressive disease, respectively. Twenty-four (65%) and 13 (35%) patients showed a maintained\/improved and deteriorated Child-Pugh-score, respectively. While baseline clinical data, treatment response, and laboratory data were similar between these two patient groups, baseline ANG2 and VEGF levels were significantly higher (<jats:italic>P<\/jats:italic>= 0.0017) and lower (<jats:italic>P<\/jats:italic>= 0.0231), respectively, in patients with deteriorated Child-Pugh score than in those without. Based on receiver operating characteristic curve analysis, cut-off values for ANG2 and VEGF were found to be 3,108 pg\/mL and 514.9 pg\/mL, respectively. Among patients with low VEGF and high ANG2, 89% (8\/9) exhibited a deteriorated Child-Pugh score, whereas none of the patients (0\/9) with high VEGF and low ANG2 did. The deterioration of the Child-Pugh score in patients with unresectable HCC who are treated with lenvatinib may be predictable based on combined baseline serum ANG2 and VEGF levels.<\/jats:p>","DOI":"10.1371\/journal.pone.0247728","type":"journal-article","created":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T18:25:42Z","timestamp":1614623142000},"page":"e0247728","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma"],"prefix":"10.1371","volume":"16","author":[{"given":"Taku","family":"Shigesawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-9106","authenticated-orcid":true,"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Maehara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshimasa","family":"Tokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akinori","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ren","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Furuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Baba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitagataya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuharu","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatsugu","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kawagishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Sho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuteru","family":"Natsuizaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,3,1]]},"reference":[{"issue":"9399","key":"pone.0247728.ref001","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"JM Llovet","year":"2003","journal-title":"The Lancet"},{"issue":"32","key":"pone.0247728.ref002","doi-asserted-by":"crossref","first-page":"4067","DOI":"10.1200\/JCO.2012.45.8372","article-title":"Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial","volume":"31","author":"AL Cheng","year":"2013","journal-title":"J Clin Oncol"},{"issue":"28","key":"pone.0247728.ref003","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1200\/JCO.2012.48.4410","article-title":"Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study","volume":"31","author":"PJ Johnson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"pone.0247728.ref004","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1200\/JCO.2013.54.3298","article-title":"Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial","volume":"33","author":"C Cainap","year":"2015","journal-title":"J Clin Oncol"},{"issue":"4","key":"pone.0247728.ref005","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"JM Llovet","year":"2008","journal-title":"N Engl J Med"},{"issue":"10064","key":"pone.0247728.ref006","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S0140-6736(16)32453-9","article-title":"Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"389","author":"J Bruix","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"pone.0247728.ref007","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"AX Zhu","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10126","key":"pone.0247728.ref008","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"M Kudo","year":"2018","journal-title":"Lancet"},{"issue":"20","key":"pone.0247728.ref009","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"RS Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"pone.0247728.ref010","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.jhep.2005.10.013","article-title":"Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies","volume":"44","author":"G D\u2019Amico","year":"2006","journal-title":"J Hepatol"},{"key":"pone.0247728.ref011","article-title":"Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR 1\u20133 signaling, but not FGFR4 signaling","author":"T Shigesawa","year":"2020","journal-title":"Carcinogenesis"},{"issue":"1","key":"pone.0247728.ref012","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/hepr.13243","article-title":"Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis","volume":"49","author":"A Hiraoka","year":"2019","journal-title":"Hepatol Res"},{"issue":"4","key":"pone.0247728.ref013","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1159\/000507022","article-title":"Potential of Lenvatinib for an Expanded Indication from the REFLECT Trial in Patients with Advanced Hepatocellular Carcinoma","volume":"9","author":"S Maruta","year":"2020","journal-title":"Liver Cancer"},{"issue":"5","key":"pone.0247728.ref014","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/jgh3.12339","article-title":"Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma","volume":"4","author":"T Shigesawa","year":"2020","journal-title":"JGH Open"},{"issue":"1","key":"pone.0247728.ref015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000503577","article-title":"(18)F-Fluorodeoxyglucose Uptake in Hepatocellular Carcinoma as a Useful Predictor of an Extremely Rapid Response to Lenvatinib","volume":"9","author":"Y Kawamura","year":"2020","journal-title":"Liver Cancer"},{"issue":"1","key":"pone.0247728.ref016","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/jgh3.12209","article-title":"Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting","volume":"4","author":"T Sho","year":"2020","journal-title":"JGH Open"},{"issue":"8","key":"pone.0247728.ref017","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1111\/hepr.13511","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria","volume":"50","author":"T Sho","year":"2020","journal-title":"Hepatol Res"},{"issue":"7","key":"pone.0247728.ref018","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1111\/hepr.13505","article-title":"Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma","volume":"50","author":"T Terashima","year":"2020","journal-title":"Hepatol Res"},{"issue":"29","key":"pone.0247728.ref019","doi-asserted-by":"crossref","first-page":"12018","DOI":"10.1073\/pnas.1301331110","article-title":"Anti-VEGF- and anti-VEGF receptor-induced vascular alteration in mouse healthy tissues","volume":"110","author":"Y Yang","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"pone.0247728.ref020","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"R Lencioni","year":"2010","journal-title":"Seminars in liver disease"},{"issue":"10","key":"pone.0247728.ref021","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/hepr.13411","article-title":"Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update","volume":"49","author":"N Kokudo","year":"2019","journal-title":"Hepatol Res"},{"issue":"1","key":"pone.0247728.ref022","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s10637-019-00801-8","article-title":"Sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: a multicenter retrospective study in Japan","volume":"38","author":"S Ogasawara","year":"2020","journal-title":"Invest New Drugs"},{"issue":"1","key":"pone.0247728.ref023","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000503031","article-title":"Post-Progression Treatment Eligibility of Unresectable Hepatocellular Carcinoma Patients Treated with Lenvatinib","volume":"9","author":"A Hiraoka","year":"2020","journal-title":"Liver Cancer"},{"issue":"6","key":"pone.0247728.ref024","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1073\/pnas.1714446115","article-title":"Context-dependent functions of angiopoietin 2 are determined by the endothelial phosphatase VEPTP","volume":"115","author":"T Souma","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pone.0247728.ref025","doi-asserted-by":"crossref","first-page":"e70459","DOI":"10.1371\/journal.pone.0070459","article-title":"Angiopoietin-2 is critical for cytokine-induced vascular leakage","volume":"8","author":"AV Benest","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"pone.0247728.ref026","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/hepr.13490","article-title":"High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C","volume":"50","author":"N Kawagishi","year":"2020","journal-title":"Hepatol Res"},{"issue":"2","key":"pone.0247728.ref027","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jcp.21229","article-title":"Flow-dependent regulation of angiopoietin-2","volume":"214","author":"W Goettsch","year":"2008","journal-title":"J Cell Physiol"},{"issue":"3","key":"pone.0247728.ref028","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/hep.29911","article-title":"Liver Angiopoietin-2 Is a Key Predictor of De Novo or Recurrent Hepatocellular Cancer After Hepatitis C Virus Direct-Acting Antivirals","volume":"68","author":"F Faillaci","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"pone.0247728.ref029","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.30230","article-title":"Serum Angiopoietin-2 Predicts Mortality and Kidney Outcomes in Decompensated Cirrhosis","volume":"69","author":"AS Allegretti","year":"2019","journal-title":"Hepatology"},{"issue":"3","key":"pone.0247728.ref030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/hep.30294","article-title":"Angiopoietin-2 Promotes Pathological Angiogenesis and Is a Therapeutic Target in Murine Nonalcoholic Fatty Liver Disease","volume":"69","author":"S Lefere","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"pone.0247728.ref031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13075-017-1304-2","article-title":"Tie2 as a novel key factor of microangiopathy in systemic sclerosis","volume":"19","author":"F Moritz","year":"2017","journal-title":"Arthritis Res Ther"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247728","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T06:34:37Z","timestamp":1697956477000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0247728"}},"subtitle":[],"editor":[{"given":"Tatsuo","family":"Kanda","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,3,1]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2021,3,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0247728","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,1]]}}}